69 results about "Aldehyde dehydrogenase (NAD+)" patented technology

The invention discloses a Lactobacillus paracasei grx06 and an application thereof in the aspects of dispelling the effects of alcohol and protecting the liver, the strain number of the Lactobacillus paracasei is grx06, the Lactobacillus paracasei is preserved in the China General Microbiological Culture Collection Center on February 18, 2025, and the preservation number is CGMCC No: 33560. The lactobacillus paracasei obtained by screening in the invention has the capability of producing ethanol dehydrogenase and acetaldehyde dehydrogenase at high yield, and is high in ethanol tolerance. In addition, the traditional Chinese medicine composition has the effects of promoting ethanol metabolism in rats and recovering liver injury. Wide application prospects are realized in the field of anti-alcohol and liver-protecting products.

The invention relates to a method for producing vanillin from natural lignocellulose biomass through co-culture of pichia pastoris, which comprises the following steps: respectively constructing a xylan hydrolysis recombinant strain (for releasing ferulic acid) and a vanillin synthesis recombinant strain (for converting ferulic acid) to realize conversion production from a natural xylan substrate to vanillin. In order to reduce the generation of by-products, 15 genes for coding aldehyde dehydrogenase (ALDRs), alcohol dehydrogenase (ADHs) and aldehyde ketoreductase (AKRs) are further knocked out from the vanillin synthesis recombinant strain, so that the vanillin can be further converted into the by-product vanillic acid, thereby improving the yield and purity of the vanillin.

Provided is a compound and so on having aldehyde dehydrogenase 2 (ALDH2) activation effect. A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound being represented by the following formula (1):whereinA is a heterocycle,R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl,R3 is an alkyl, an alkenyl, or an alkynyl, andX1 and X2 are each independently a halogen.

The invention provides polypeptides and encoding nucleic acids of aldehyde dehydrogenase variants. The invention also provides cells expressing aldehyde dehydrogenase variants. The invention further provides methods for producing 3-hydroxybutyraldehyde (3-HBal) and / or 1,3-butanediol (1,3-BDO), or an ester or amide thereof, comprising culturing cells expressing an aldehyde dehydrogenase variant or using lysates of such cells. The invention additional provides methods for producing 4-hydroxybutyraldehyde (4-HBal) and / or 1,4-butanediol (1,4-BDO), or an ester or amide thereof, comprising culturing cells expressing an aldehyde dehydrogenase variant or using lysates of such cells.

This invention relates to a hangover relief composition containing a dried powder, lysate, or extract of enzymes that produce glutathione and aldehyde dehydrogenase. Specifically, this invention relates to a hangover relief composition containing dried powder, lysate, or extract of *Saccharomyces cerevisiae* Kwon P-1 KCTC 13925BP, *Saccharomyces cerevisiae* Kwon P-2 KCTC14122BP, and *Saccharomyces cerevisiae* Kwon P-3 KCTC14123BP, which simultaneously produce glutathione and aldehyde dehydrogenase.

The invention provides polypeptides and encoding nucleic acids of aldehyde dehydrogenase variants. The invention also provides cells expressing aldehyde dehydrogenase variants. The invention further provides methods for producing 3-hydroxybutyraldehyde (3-HBal) and / or 1,3-butanediol (1,3-BDO), or an ester or amide thereof, comprising culturing cells expressing an aldehyde dehydrogenase variant or using lysates of such cells. The invention additional provides methods for producing 4-hydroxybutyraldehyde (4-HBal) and / or 1,4-butanediol (1,4-BDO), or an ester or amide thereof, comprising culturing cells expressing an aldehyde dehydrogenase variant or using lysates of such cells.

The present invention discloses the construction and application of a recombinant Gluconobacter oxydans, belonging to the fields of genetic engineering and whole-cell catalysis. The present invention heterologously expresses an epoxide hydrolase from Sphingomonas in Gluconobacter oxydans, and simultaneously utilizes the alcohol and aldehyde dehydrogenases bound to the membrane of Gluconobacter oxydans itself to synthesize R-mandelic acid in a one-step process using styrene oxide as a substrate. The present invention combines the transcriptome data of Gluconobacter oxydans, screens 7 strong promoters using green fluorescent protein as a reporter gene, and determines the strongest promoter P for expressing the epoxide hydrolase gene. 12780 , ultimately significantly increasing the yield of R-mandelic acid.

Process for the production of 5-hydroxymethyl-2-furancarboxylic acid (HMFA), wherein 5-hydroxymethylfurfural (HMF), which is present in an aqueous solution, is oxidized to obtain 5-hydroxymethyl-2-furancarboxylic acid (HMFA) by treatment with an NAD(P)+-dependent aldehyde dehydrogenase in vitro with NAD(P)H being formed; after said oxidation step the NAD(P)H formed during the oxidation is enzymatically regenerated with an oxidoreductase back to NAD(P)+, and a keto compound is used as a cosubstrate of the oxidoreductase.

Provided is a genetically engineered strain of Saccharomyces cerevisiae ST100-Suc3 for producing succinic acid. The Saccharomyces cerevisiae ST100-Suc3 is obtained by overexpressing malate dehydrogenase (ScMDH3R), fumarase (RoFUM) and fumarate reductase (TbFRD) in Saccharomyces cerevisiae PY-EDS8 while knocking out a glycerol-3-phosphate dehydrogenase (GPD1) gene, an alcohol dehydrogenase (ADH1) gene and an aldehyde dehydrogenase (ALD6) gene. The Saccharomyces cerevisiae strain is Saccharomyces cerevisiae PY-EDS8, with the deposit number GDMCC No: 63815. The strain exhibits tolerance to high-concentration succinic acid and can grow in a liquid medium supplemented with 100 g / L of succinic acid (pH=2.68), but produces almost no succinic acid.

The invention discloses an mRNA medicine of acetaldehyde dehydrogenase and application of the mRNA medicine, and belongs to the technical field of biological medicine. An mRNA coding optimization design is carried out based on an ALDH2 amino acid sequence, and a candidate molecule YQTQ-01 with high expression performance is obtained through in-vitro expression screening. Wild type mouse in-vivo experiments prove that the molecule can significantly improve the expression level of ALDH2 protein, and subsequent mouse pharmacodynamic studies show that the molecule has a definite aldehyde metabolism regulation function. Experimental data reveals that the YQTQ-01 can effectively promote removal of toxic aldehyde substances by enhancing the activity of acetaldehyde dehydrogenase, and a novel intervention scheme is provided for treatment of alcoholic liver injury, aldehyde metabolic disturbance and other diseases.

A production method according to one embodiment is a method for producing 4-(aminomethyl)cyclohexane-1-carboxylic acid from 1,4-bis(aminomethyl)cyclohexane using a protein consisting of an amino acid sequence having 60% or more identity to an amino acid sequence shown in any one of SEQ ID NOs. 1 to 4 and 103 to 105 and having transamination activity, and a protein consisting of an amino acid sequence having 50% or more identity to an amino acid sequence shown in any one of SEQ ID NOs. 19 to 22, 35 to 46 and 127 to 139 and having aldehyde dehydrogenase activity.

The application discloses an aldolase bioelement screening method and related application of a series of aldolases in catalyzing a condensation reaction of formaldehyde and pyruvic acid to synthesize 4-hydroxy-2-ketobutyric acid. The aldolase provided by the application is a protein shown in SEQ ID NO. 1-NO. 10, or a functionally identical protein obtained through substitution and / or deletion / addition of one or more amino acid residues. The aldolase has the following characteristics: 1) belonging to the HpcH functional domain family protein; 2) the sequence length is 240-320 amino acids; 3) the existing database function annotation is 4-hydroxy-2-oxovalerate aldolase (can catalyze the condensation reaction of acetaldehyde and pyruvic acid); the aldolase can take formaldehyde and pyruvic acid as substrates, and can carry out enzyme catalysis reaction in appropriate conditions and medium, and can efficiently biosynthesize 4-hydroxy-2-ketobutyric acid, and has the remarkable characteristics of mild reaction condition, good stereoselectivity and no pollution.

The invention relates to the technical field of biology, and discloses a genetically engineered bacterium for high yield of 1, 4-butanediol and application of the genetically engineered bacterium. Escherichia coli is used as a chassis bacterium, a gene ldhA for coding lactic dehydrogenase, a gene adhE for coding ethanol dehydrogenase, a gene pflB for coding formate lyase, and a gene gabD and a gene yneI for coding succinate semialdehyde dehydrogenase are knocked out from a chassis bacterium genome, expression of a succinate semialdehyde dehydrogenase gene sucD and a 4-hydroxybutyrate dehydrogenase gene 4hbD is strengthened, a pdhR gene is knocked out, and a recombinant plasmid is obtained. The expression of the gene gltAR164L is enhanced, the gene mdh, the gene arcA, the gene poxB, the gene sdhAB and the gene ptsG are knocked out, and the expression of the glf gene and the ppc gene is enhanced; the method comprises the following steps of: transferring plasmids carrying a gene ald for coding aldehyde dehydrogenase, a gene cat2 for coding acyltransferase and a gene yqhD for coding alcohol dehydrogenase into a chassis bacterium, and carrying out metabolic transformation to obtain a genetically engineered bacterium which carries exogenous plasmids and has the capabilities of high yield and extracellular accumulation of 1, 4-BDO, so that the yield of 1, 4-BDO can be increased to 4.71 g / L.

The present invention relates to food and pharmaceutical compositions for inhibiting tremor or dyskinesia comprising a novel aldehyde dehydrogenase encoded by a gene having more than 98% homology with the gene of SEQ ID NO: 1. Furthermore, the present invention relates to a food composition and a pharmaceutical composition for inhibiting tremor or dyskinesia, said composition comprising a lysate of any one selected from the group consisting of KCTC 13925BP, KCTC 14122BP, KCTC 14123BP, KCTC 14983BP, KCTC 14984BP and KCTC 14985BP, or a mixture thereof.

The invention relates to a method for producing 5-hydroxymethyl-2-furancarboxylic acid (HMFA), wherein 5-hydroxymethylfurfural (HMF), which is present in an aqueous solution, is oxidized in order to form 5-hydroxymethyl-2-furancarboxylic acid (HMFA) by means of a treatment using an NAD(P)+-dependent aldehyde dehydrogenase in vitro, thereby forming NAD(P)H, after which the NAD(P)H formed during the oxidation process is enzymatically regenerated using an NAD(P)H oxidase in order to form NAD(P)+. The method is characterized in that the NAD(P)H oxidase comprises an amino acid sequence selected from the group consisting of: i) an amino acid sequence which has an identity of at least 80% to SEQ ID No. 14, SEQ ID No. 16, or SEQ ID No. 18, ii) an amino acid sequence encoded by a nucleic acid which has an identity of at least 80% to SEQ ID No. 13, SEQ ID No. 15, or SEQ ID No. 17, and iii) an amino acid sequence encoded by a nucleic acid which, under stringent conditions, binds to a nucleic acid molecule having the nucleic acid sequence SEQ ID No. 13, SEQ ID No. 15, or SEQ ID No. 17.

The present invention provides recombinant Escherichia coli for producing glutarate, a construction method and use thereof. A double-plasmid recombinant bacterium is constructed through molecular biological means for co-expressing an aldehyde synthase (AAS) gene, an amine oxidase Mao (gene) and an aldehyde dehydrogenase (Glox) gene. The constructed expression plasmids are introduced into the Escherichia coli to reconstruct to obtain recombinant cells. A recombination strain for efficiently producing glutarate is obtained through amicillin resistance and kanamycin resistance combined plate screening. Efficient production of the glutarate is achieved by optimizing concentration of a substrate, cell concentration and a transformation temperature. L-lysine with a concentration of 30 g / L may be transformed into 19.65 g of glutarate through reactions for 30 h under transformation conditions that the cell concentration is 30 g / L, the pH value is 8 and 6 mM of NAD+ is additionally added, wherein a transformation rate may be 65.3%.

The present application relates to a kind of high 4-HBC mycobacterium genetic engineering bacteria and its construction method, and its application in the microbial fermentation preparation 22-hydroxy-23, 24-bis-norcholesta-4-en-3-ketone of 4-HBC.The high 4-HBC mycobacterium genetic engineering bacteria is constructed as follows: with mycobacterium as chassis, kshA1, kshA2, kstD1, kstD2, kstD3 gene is knocked out in turn, hsd4A gene is knocked out, ltp3, ltp4 gene is overexpressed, and the high 4-HBC mycobacterium genetic engineering bacteria is obtained.The genetic engineering bacteria provided in the present application can produce 4-HBC, greatly improve the production efficiency of steroidal drugs, help to improve the conversion rate of substrate, reduce production cost, and reaction condition is mild, environment-friendly, suitable for vigorous popularization and application, with higher economic benefit and social benefit.

To provide aldehyde dehydrogenase variants.SOLUTION: The invention provides polypeptides and encoding nucleic acids of aldehyde dehydrogenase variants. The invention also provides cells expressing the variants. The invention further provides methods for producing 3-hydroxybutyraldehyde (3-HBal) and / or 1,3-butanediol (1,3-BDO), or an ester or amide thereof, the methods comprising culturing cells expressing an aldehyde dehydrogenase variant, or using lysates of such cells. The invention additionally provides methods for producing 4-hydroxybutyraldehyde (4-HBal) and / or 1,4-butanediol (1,4-BDO), or an ester or amide thereof, the methods comprising culturing cells expressing an aldehyde dehydrogenase variant, or using lysates of such cells.SELECTED DRAWING: Figure 1

Disclosed are compositions and methods for inhibiting aldehyde dehydrogenases. In further aspects, treatment of cancers by inhibiting aldehyde dehydrogenases with the disclosed compositions are also disclosed.

Abstract Disclosed are biosynthetic methods and engineered microorganism that enhance or improve the biosynthesis of hexamethylenediamine, caproic acid or caprolactam. The engineered microorganisms include selected aldehyde dehydrogenase activity. Abstract 1 / 10 wo 2020 / 219863 PCT / US2020 / 029793 +HO2C 5CoA 5CoA SUCCINYL-CoA ACETYL-CoA A A HO2C 5CoA E,F,G HO2C 002H 3-OXOADIPL-CoA 3-OXOADIPATE B H OH OH HO2C 5CoA HO2C 002H 3-HYDROXYADIPYL-CoA 3-HYDROXYDIPATE C 000000 HO2C 5CoA HO2C OO2H 3-CARBOXY-2-PENTENOYL-CoA 5-CARBOXY-2-PENTENOATE D K,L,M HOC 5CoA HO2C OO2H ADIPYL-CoA ADIPATE X N Y H Z HO2C HO2C OPO3 ADIPATE SEMIALDEHYDE ADIPYLPHOSPATE O,P HO2C NH 6-AMINOCAPROATE S Q,R CoAS NH NH T 6-AMINOCAPROYL-CoA CAPROLACTAM U H V,WNH2 H2N NH2 6-AMINOCAPROATE SEMIALDEHYDE HEXAMETYLENEDIAMINE Fig. 1 SUBSTITUTE SHEET (RULE 26) 20 26 20 48 92 24 J un 2 02 6 1 / 1 0 w o 2 0 2 0 / 2 1 9 8 6 3 P C T / U S 2 0 2 0 / 0 2 9 7 9 3 2 0 2 6 2 0 4 8 9 2 2 4 J u n 2 0 2 6 A 5 C o A E , F , G H O 2 C O O 2 H 3 - O X O A D I P L - C o A 3 - O X O A D I P A T E B H O H O H 5 C o A H O 2 C 0 0 2 H 3 - H Y D R O X Y D I P A T E C 000000 H O 2 C 5 C o A O O 2 H 3 - C A R B O X Y - 2 - P E N T E N O Y L - C o A J O O 2 H 5 C o A H O 2 C A D I P Y L - C o A A D I P A T E X N Y H Z H O 2 C H O 2 C O P O 3 A D I P Y L P H O S P A T E H O 2 C N H 6 - A M I N O C A P R O A T E S Q , R C o A S N H N H 2 T 6 - A M I N O C A P R O Y L - C o A C A P R O L A C T A M U H V , W N H H 2 N N H 2 6 - A M I N O C A P R O A T E S E M I A L D E H Y D E H E X A M E T Y L E N E D I A M I N E F i g . 1 S U B S T I T U T E S H E E T ( R U L E 2 6 )

The present invention is directed to a food or pharmaceutical composition for improving behavior and motor function, and a pharmaceutical composition for inhibiting or preventing Parkinson's disease, which contains an aldehyde dehydrogenase encoded by a gene having more than 98% homology to the gene of SEQ ID NO: 1, particularly encoded by the gene of SEQ ID NO: 1 including SEQ ID NO: 2, and contained in a lysate of any one or a mixture thereof selected from the group consisting of Saccharomyces cerevisiae, KCTC13925BP, KCTC14122BP, KCTC14123BP, KCTC14983BP, KCTC14984BP and KCTC14985BP.

The invention relates to an Escherichia coli engineering strain for producing 2, 3-hexanediol as well as a construction method and application of the Escherichia coli engineering strain, and the method comprises the following steps: constructing recombinant plasmids pET-FadB-Ter-PhaA for expressing FadB genes of 3-hydroxyacetyl-CoA dehydrogenase and enoyl-CoA hydratase, Ter genes of trans-enoyl-CoA reductase and PhaA genes of acetyl-CoA acetyltransferase; the method comprises the following steps: constructing a recombinant plasmid pRSF-Ilv2C-PduP for expressing an Ilv2C gene of acetohydroxy acid synthetase and a PduP gene of CoA-acylated aldehyde dehydrogenase; and chemically converting the recombinant plasmid pET-FadB-Ter-PhaA and the recombinant plasmid pRSF-Ilv2C-PduP into escherichia coli, so as to obtain the escherichia coli engineering strain for producing the 2, 3-hexanediol. The Escherichia coli engineering strain realizes microbial de novo synthesis of linear beta, gamma-hexanediol for the first time, fills the vacancy in the field of biosynthesis of dihydric alcohol, and expands the application prospect of dihydric alcohol.

This invention relates to the field of biological products, and particularly to the preparation and application of hangover relief products. This invention provides an alcohol dehydrogenase mutant, an aldehyde dehydrogenase mutant, an expression vector, a combination of recombinant yeast strains, and yeast single-cell oral capsules. By cloning the alcohol dehydrogenase and aldehyde dehydrogenase genes into the *Saccharomyces cerevisiae* expression plasmid pYX212, and then transforming the *Saccharomyces cerevisiae* into the *Saccharomyces cerevisiae*, engineered yeast is obtained. Utilizing the protective effect of yeast cells, oral administration is achieved, effectively reducing the destruction of recombinant enzymes by gastric juice. The yeast single-cell oral capsules can accelerate alcohol metabolism after daily drinking and promote hepatocyte regeneration; they are convenient and quick to take and have significant effects.

The present disclosure provides: a variant of a low-specific threonine aldolase; a microorganism comprising the variant; a microorganism comprising the variant and exhibiting enhanced aldehyde dehydrogenase activity; a method for producing at least one amino acid selected from the group consisting of glycine, alanine, and valine, the method comprising a step of culturing the microorganism; and a composition for producing the at least one amino acid, the composition comprising the microorganism. The microorganism exhibits an excellent ability to produce at least one amino acid selected from the group consisting of glycine, alanine, and valine.

A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound represented by the following formula (1): wherein A is a heterocycle, R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl, R3 is an alkyl, an alkenyl, or an alkynyl, L is absent or an alkylene, X1 is a halogen, and X2 is hydrogen or a halogen.

Compositions of the present invention comprise novel aldehyde dehydrogenases derived from novel mutant yeasts, which improve memory and cognitive functions. The present invention relates to food and pharmaceutical compositions for preventing Alzheimer's disease and Huntington's disease by reducing accumulation of diseased proteins in brain tissue. The food or pharmaceutical composition of the present invention comprises a lysate of any one selected from the group consisting of Saccharomyces cerevisiae KCTC 13925BP, KCTC 14122BP, KCTC 14123BP, KCTC 14983BP, KCTC 14984BP, and KCTC 14985BP, or a mixture thereof. The food or pharmaceutical composition of the present invention comprises a lysate of any one selected from the group consisting of KCTC 13925BP, KCTC 14122BP, KCTC 14123BP, KCTC 14984BP, and KCTC 14985BP.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to an amide aldehyde dehydrogenase agonist, a synthesis method and purposes thereof. The amide compound provided by the application shows higher agonistic activity to ALDH2, so the compound has the potential to prepare a therapeutic drug for a disease related to ALDH2 activity; (2) the amide compound of the application has obviously improved activity and water solubility compared with a positive control, and has better drug property. Therefore, the compound of the application has a good development prospect.

Disclosed are compositions and methods for inhibiting aldehyde dehydrogenases. In further aspects, treatment of cancers by inhibiting aldehyde dehydrogenases with the disclosed compositions are also disclosed.

A method of selectively inhibiting aldehyde dehydrogenase 1a1 (ALDH1a1) relative to aldehyde dehydrogenase 2 (ALDH2) in a subject may include administering to the subject in need thereof, an effective amount of a disulfiram derivative having a structure which may be substituted and is optionally a salt, solvate, tautomer, stereoisomer, or mixture thereof, thereby selectively inhibiting the ALDH1A1 relative to ALDH2 in the subject. An aldehyde dehydrogenase 1a1 (ALDH1a1)-selective antagonist composition, may include such a disulfiram derivative and a pharmaceutically acceptable carrier and / or excipient.